Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Mitomycin C
AEON Biopharma
Glaucoma
1 trial -
Modakafusp Alfa
Teva Pharma GmbH
Neoplasms
1 trial -
Modakafusp alfa
Teva Pharma GmbH
Multiple Myeloma
3 trials -
Molindone
SUPERNUS PHARMACEUTICALS, INC.
Impulsive Aggression Comorbid With ADHD in Children
1 trial -
Mometasone furoate
Teva Pharma GmbH
Seasonal Allergic Rhinitis
1 trial -
N-Acetylcysteine (NAC)
CUMBERLAND PHARMACEUTICALS INC
Radiocontrast Nephropathy
1 trial -
NAPROXEN SODIUM, DESOGESTREL, TRAMADOL HYDROCHLORIDE, IBUPROFEN, Placebo to match AMY109, Placebo to match desogestrel, Feanolla 75 microgram film-coated tablets, CODEINE PHOSPHATE, PARACETAMOL, NAPROXEN, AMY109
Lacuna Pharma Pty Ltd
Endometriosis
1 trial -
NAT01, NAT03, Placebo film coated tablets, NAT02
Dr. Falk Pharma GmbH
Idiopathic or Diabetic Gastroparesis
1 trial -
NMD670, NMD670, Placebo
Lacuna Pharma Pty Ltd
Myasthenia Gravis
1 trial -
NMD670, Placebo
Lacuna Pharma Pty Ltd
Charcot-Marie-Tooth Disease Type 1 and Type 2
1 trial -
NOE-105, Placebo, Hard Capsules
Lacuna Pharma Pty Ltd
Tourette Syndrome
1 trial -
NS-229 matching tablets with no active treatment, NS-229
Lacuna Pharma Pty Ltd
Eosinophilic granulomatosis with polyangiitis (EGPA)
1 trial -
NV-5138
SUPERNUS PHARMACEUTICALS, INC.
Major Depressive Disorder
1 trial -
NV-5138
SUPERNUS PHARMACEUTICALS, INC.
Treatment Resistant Depression
1 trial -
NX210c, GLUCOSE 5 % B.BRAUN, solution pour perfusion
Lacuna Pharma Pty Ltd
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
NXC-201 CAR-T
Immix Biopharma
Light Chain (AL) Amyloidosis
1 trial -
NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)
Pari Pharma GmbH
The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.
1 trial -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
NMO Spectrum Disorder
1 trial -
Nabiximols
Jazz Pharmaceuticals Ireland Limited
Glioblastoma
1 trial -
Namodenoson
Can-Fite BioPharma
NASH - Nonalcoholic Steatohepatitis
1 trial -
Namodenoson 25mg
Can-Fite BioPharma
Pancreatic Adenocarcinoma
1 trial -
Namodenoson, Matching placebo for namodenoson
Can-Fite BioPharma
Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis
1 trial -
Nebulized IVX-0142
Teva Pharma GmbH
Asthma
1 trial -
Neflamapimod
Lacuna Pharma Pty Ltd
Dementia with Lewy Bodies (DLB)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources